Bedrijfsoverzicht
Plus Therapeutics, Inc. operates as a clinical-stage pharmaceutical company dedicated to the development, manufacture, and commercialization of therapeutic treatments specifically designed for patients suffering from cancer. The organization functions within the healthcare sector and the biotechnology industry, a classification that implies a high degree of scientific risk and a reliance on successful clinical trial outcomes to generate future commercial value. At present, the company employs a workforce of 28 individuals, reflecting a small-scale operational structure typical of early-stage biotech firms. The company's current market capitalization stands at $32.94M, while its trailing twelve-month revenue is recorded at $5.21M, figures that collectively indicate a micro-cap status with limited market penetration and a reliance on external capital to fund research and development activities before achieving profitability.
Financiële gezondheid
The company reported a revenue of $5.21M over the trailing twelve months, yet it simultaneously recorded a net income of $-22,386,000 and an EBITDA of $-14,853,000. The substantial disparity between the positive revenue figure and the deeply negative net income reveals a cost structure where operating expenses, likely dominated by research and development costs, far exceed total sales, resulting in a significant pre-tax loss. Free cash flow is reported at $-13,597,750, which indicates that the company is consuming cash reserves to fund its operations and development pipeline rather than generating cash from its current business model. This negative cash flow suggests limited financial flexibility, necessitating continued access to capital markets or existing cash reserves to sustain operations. The gross margin stands at -60.7%, the operating margin is -420.0%, and the profit margin is 0.0%; these negative figures highlight that the company has not yet achieved the operational efficiencies or revenue scale required to cover its fixed and variable costs. On the balance sheet, the company holds $8.61M in cash against $821,000 in debt, supported by a debt-to-equity ratio of 20.55. Despite the high leverage ratio relative to equity, the absolute debt load is low compared to cash on hand, though the negative earnings contribute to a leveraged financial profile. The current ratio is 1.23, indicating that the company possesses sufficient short-term assets to cover its short-term liabilities, though the buffer is relatively narrow. Return on Equity is listed as N/A due to the lack of positive retained earnings, while Return on Assets is -83.3%, a metric that reveals that the company's assets are currently generating negative returns for its stakeholders.
Waarderingsbeoordeling
Valuation metrics for Plus Therapeutics present a complex picture due to the company's lack of profitability, with a P/E Ratio (TTM) listed as N/A and a Forward P/E of -2.04. The absence of a trailing P/E ratio implies that traditional earnings-based valuation models are inapplicable, while the negative forward P/E suggests that analysts or market data providers anticipate earnings will remain negative in the coming year. The price-to-book ratio is calculated at 6.67, which indicates that the market is pricing the company at a significant premium over its book value, a common occurrence in biotech sectors where intangible assets like patent rights are not fully reflected on the balance sheet. Alternative valuation multiples show a price-to-sales ratio of 6.32 and an EV/EBITDA of -1.69; these metrics suggest that the company is valued based on revenue potential and cash burn rather than current profitability, reflecting high expectations for future product approvals. The stock's trading range over the past year spans a 52-week high of $30.50 and a 52-week low of $2.90. Given the volatility inherent in the biotechnology sector, the current price position relative to this wide range must be interpreted with caution, noting that the stock trades well below the 52-week high and significantly above the 52-week low. The beta value is 1.02, which means the stock's price volatility is nearly identical to the broader market, indicating that the company does not offer a significant hedge against or amplification of general market movements compared to a beta-neutral position.
Growth & Income
Revenue growth year-over-year is -3.2%, while earnings growth year-over-year is N/A due to the company's continued losses. The fact that revenue is contracting while the company remains in a loss-making phase implies that the top-line is not yet sufficient to offset the high fixed costs associated with clinical-stage development. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, indicating that no cash is distributed to shareholders. This reinvestment strategy is standard for clinical-stage biotechs, where earnings are theoretically directed toward growth initiatives such as advancing their lead radiotherapeutic candidate, rhenium obisbemeda, rather than being paid out. The overall growth and income profile is characterized by negative revenue momentum and a complete lack of dividend income, highlighting the speculative nature of the investment which relies entirely on future clinical successes to transform the financial trajectory.